SanBio Co (JP:4592) has released an update.
SanBio Co., Ltd. has announced the conditional and time-limited marketing approval in Japan for ‘AKUUGO🄬🄬’, a novel treatment for chronic motor paralysis due to traumatic brain injury (TBI). This groundbreaking therapy, the first of its kind globally, has the potential to regenerate brain function and improve patients’ quality of life. SanBio is preparing for commercial production with plans to commence shipping and sales in early 2026, while also exploring further applications for ischemic stroke treatment.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.